Platform Strategies for Synthetic Oligonucleotide Drug Substances-Reference-Cited by-同舟云学术

Platform Strategies for Synthetic Oligonucleotide Drug Substances

Published:2023-11-30 Issue:12 Volume:27 Page:2211-2222
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Altevogt Dominik¹^ORCID,Cedillo Isaiah²^ORCID,Curtis Corrine³^ORCID,Diorazio Louis J.⁴^ORCID,Faber Jesse⁵^ORCID,Jones Michael T.⁶^ORCID,Telford Alex⁴,Turner Gillian⁷^ORCID,Wetter Christian⁸^ORCID

Affiliation:

1. Novartis AG, Lichtstrasse 35, Basel CH-4056, Switzerland

2. Ionis Pharmaceuticals Inc., 2855 Gazelle Court, Carlsbad, California 92010, United States

3. Janssen Research and Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United States

4. Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom

5. Manufacturing Sciences, Pharmaceutical Operations & Technology, Biogen Inc., 900 Davis Drive, Research Triangle Park, North Carolina 27709, United States

6. Pfizer Inc., 875 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States

7. GSK, Gunnels Wood Rd, Stevenage SG1 2NY, United Kingdom

8. F. Hoffmann-La Roche AG, Grenzacherstrasse 124, Basel CH-4070, Switzerland

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.3c00303

Reference13 articles.

1. European Pharma Oligonucleotide Consortium A Move to Consolidate Oligonucleotide Knowledge and Share Experience Within the Community

2. Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease

3. Impurities in Oligonucleotide Drug Substances and Drug Products

4. Perspectives on the Designation of Oligonucleotide Starting Materials

5. Acid binding and detritylation during oligonucleotide synthesis